249 related articles for article (PubMed ID: 33382906)
1. Adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis.
Yin X; Zhao Z; Yin Y; Shen C; Chen X; Cai Z; Wang J; Chen Z; Yin Y; Zhang B
Clin Transl Sci; 2021 May; 14(3):919-933. PubMed ID: 33382906
[TBL] [Abstract][Full Text] [Related]
2. Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis.
Zhou S; Kishi N; Alerasool P; Rohs NC
Target Oncol; 2024 Jun; ():. PubMed ID: 38824269
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
Zhao P; Zhen H; Zhao H; Zhao L; Cao B
BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
[TBL] [Abstract][Full Text] [Related]
5. Diarrhea with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: A meta-analysis of randomized controlled trials.
Li J; Gu J
Crit Rev Oncol Hematol; 2019 Feb; 134():31-38. PubMed ID: 30771871
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Qi YT; Hou Y; Qi LC
Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
[TBL] [Abstract][Full Text] [Related]
7. Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: Pooled analysis and subgroup analysis of efficacy and safety.
Xu R; Shao H; Zhu J; Ju Q; Shi H
Medicine (Baltimore); 2019 Mar; 98(13):e14135. PubMed ID: 30921175
[TBL] [Abstract][Full Text] [Related]
8. Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients: A network meta-analysis.
Wu Z; Chen S; Du X; Wu Y; Xie X
J Clin Pharm Ther; 2021 Apr; 46(2):310-318. PubMed ID: 33031574
[TBL] [Abstract][Full Text] [Related]
9. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
[TBL] [Abstract][Full Text] [Related]
10. Fatigue with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: A meta-analysis of randomized controlled trials.
Li J; Sun W
J Chemother; 2018; 30(6-8):323-331. PubMed ID: 30663550
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.
Mosca M; Conci N; Di Federico A; Tateo V; Favorito V; Zappi A; Gelsomino F; De Giglio A
JCO Precis Oncol; 2023 May; 7():e2300073. PubMed ID: 37262392
[TBL] [Abstract][Full Text] [Related]
13. Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.
Ma W; Xu M; Liu Y; Liu H; Huang J; Zhu Y; Ji LJ; Qi X
Int J Cancer; 2015 Jul; 137(2):409-19. PubMed ID: 25471638
[TBL] [Abstract][Full Text] [Related]
14. Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
Sun W; Li J
Cancer Invest; 2019; 37(6):253-264. PubMed ID: 31303065
[TBL] [Abstract][Full Text] [Related]
15. EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
An N; Zhang Y; Niu H; Li Z; Cai J; Zhao Q; Li Q
Medicine (Baltimore); 2016 Dec; 95(50):e5601. PubMed ID: 27977598
[TBL] [Abstract][Full Text] [Related]
16. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.
Li YX; Yang JY; Xu YF; Zhang M; Zhang XP; Chen WY; Lv XD
Math Biosci Eng; 2019 Jun; 16(5):5687-5696. PubMed ID: 31499732
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis.
Hu D; Zhou YY; Ma HB; Tao MM; Huang QZ; Yang ZZ; Zhou Q
BMC Pulm Med; 2023 Jun; 23(1):207. PubMed ID: 37316870
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: A systematic review and meta-analysis.
Chen Y; Wen S; Wu Y; Shi L; Xu X; Shen B
Crit Rev Oncol Hematol; 2021 Jul; 163():103393. PubMed ID: 34119658
[TBL] [Abstract][Full Text] [Related]
19. The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Subramanian J; Fernandes AW; Laliberté F; Pavilack M; DerSarkissian M; Duh MS
Lung Cancer; 2019 Dec; 138():131-138. PubMed ID: 31733614
[TBL] [Abstract][Full Text] [Related]
20. A review on adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell lung cancer patients.
Biswas B; Ghadyalpatil N; Krishna MV; Deshmukh J
Indian J Cancer; 2017 Dec; 54(Supplement):S55-S64. PubMed ID: 29292709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
